J. Inciarte-Mundo
About
J. Inciarte-Mundo is a scholar working on Rheumatology, Hematology and Immunology.
According to data from OpenAlex, J. Inciarte-Mundo has authored 30 papers receiving a total of 420 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Rheumatology, 9 papers in Hematology and 8 papers in Immunology. Recurrent topics in J. Inciarte-Mundo's work include Rheumatoid Arthritis Research and Therapies (22 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Systemic Lupus Erythematosus Research (6 papers). J. Inciarte-Mundo is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (22 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Systemic Lupus Erythematosus Research (6 papers). J. Inciarte-Mundo collaborates with scholars based in Spain, United Kingdom and Venezuela. J. Inciarte-Mundo's co-authors include Raimón Sanmartí, Julio Ramírez, Juan D. Cañete, Virginia Ruíz-Esquide, M.V. Hernández, Andrea Cuervo, Jordi Yagüe, Mariona Pascal, Tatiana Dilla and José Antonio Sacristán and has published in prestigious journals such as Frontiers in Immunology, Annals of the Rheumatic Diseases and Lara D. Veeken.
In The Last Decade
J. Inciarte-Mundo
30 papers receiving 413 citations
Peers
J. Inciarte-Mundo
Jong-Liang Lan Taiwan
Jean-David Cohen France
Enrique Raya Spain
Sita Bhella Canada
Emre Bılgın Türkiye
A Smerdel Norway
Shannen Nelson United States
Lieke Tweehuysen Netherlands
Carolina Duarte‐Salazar Mexico
Maria Domenica Guarino Italy
Citations per year, relative to J. Inciarte-Mundo J. Inciarte-Mundo (= 1×)
peers
Jong-Liang Lan
Countries citing papers authored by J. Inciarte-Mundo
Since
Specialization
Citations
This map shows the geographic impact of J. Inciarte-Mundo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Inciarte-Mundo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Inciarte-Mundo more than expected).
Fields of papers citing papers by J. Inciarte-Mundo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by J. Inciarte-Mundo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Inciarte-Mundo. The network helps show where J. Inciarte-Mundo may publish in the future.
Co-authorship network of co-authors of J. Inciarte-Mundo
This figure shows the co-authorship network connecting the top 25 collaborators of J. Inciarte-Mundo. A scholar is included among the top collaborators of J. Inciarte-Mundo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Inciarte-Mundo. J. Inciarte-Mundo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ponce, Andrés, J. Inciarte-Mundo, Rosa Morlà, et al.. (2022). Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors. Therapeutic Advances in Musculoskeletal Disease. 14. 1759720X221114105–1759720X221114105.
2.
Hernández‐Cruz, Blanca, J. Rosas, Cèsar Díaz‐Torné, et al.. (2022). Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study). Rheumatology and Therapy. 9(2). 589–608.
3.
Inciarte-Mundo, J., et al.. (2022). From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. Frontiers in Immunology. 13. 1001025–1001025.
4.
Salvarani, Carlo, Marco Sebastiani, Philippe Dieudé, et al.. (2021). Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials. Rheumatology and Therapy. 8(3). 1435–1441.
5.
Ramírez, Julio, J. Inciarte-Mundo, Andrea Cuervo, et al.. (2021). Comparable long-term outcomes between DAS28-ESR remission criteria and ACR/EULAR definitions in patients with established rheumatoid arthritis. Clinical Rheumatology. 40(7). 2665–2672.
6.
Cuervo, Andrea, Raimón Sanmartí, Julio Ramírez, et al.. (2021). Palindromic rheumatism: Evidence of four subtypes of palindromic-like arthritis based in either MEFV or rheumatoid factor/ACPA status. Joint Bone Spine. 88(6). 105235–105235.
7.
Díaz‐Torné, Cèsar, Ana Urruticoechea‐Arana, J. Ivorra Cortés, et al.. (2020). What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis. Advances in Therapy. 37(4). 1479–1495.
8.
Pablos, José L., J. Inciarte-Mundo, Tatiana Dilla, et al.. (2019). Patient Decision Aid (PDA) for Patients with Rheumatoid Arthritis Reduces Decisional Conflict and Improves Readiness for Treatment Decision Making. Patient. 13(1). 57–69.
9.
Schlueter, Max, et al.. (2019). <p>Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain</p>. ClinicoEconomics and Outcomes Research. Volume 11. 395–403.
10.
Sacristán, José Antonio, Silvia Díaz‐Cerezo, Inmaculada de la Torre, J. Inciarte-Mundo, & Alejandro Balsa. (2019). Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions. Rheumatology and Therapy. 6(4). 473–477.
11.
Díaz‐Torné, Cèsar, J. Ivorra Cortés, Tatiana Dilla, et al.. (2018). PMS112 - PATIENT AND RHEUMATOLOGIST PREFERENCES FOR THE ATTRIBUTES OF RHEUMATOID ARTHRITIS TREATMENTS IN SPAIN. A DISCRETE CHOICE EXPERIMENT. Value in Health. 21. S307–S307.
12.
Inciarte-Mundo, J., Julio Ramírez, M.V. Hernández, et al.. (2018). Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. Arthritis Research & Therapy. 20(1). 275–275.
13.
Ramírez, Julio, José Antonio Narváez, Virginia Ruíz-Esquide, et al.. (2017). Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up. Seminars in Arthritis and Rheumatism. 47(3). 303–309.
14.
Gómara, María J., Juan D. Cañete, Julio Ramírez, et al.. (2017). Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis. Arthritis Research & Therapy. 19(1). 141–141.
15.
Castellanos‐Moreira, Raúl, et al.. (2017). Musculoskeletal Involvement in Hereditary Hemochromatosis. JCR Journal of Clinical Rheumatology. 23(5). 291–291.
16.
Inciarte-Mundo, J., Julio Ramírez, M.V. Hernández, et al.. (2016). Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Research & Therapy. 18(1). 160–160.
17.
Inciarte-Mundo, J., M.V. Hernández, Virginia Ruíz-Esquide, et al.. (2015). Serum Calprotectin Versus Acute‐Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. Arthritis Care & Research. 68(7). 899–906.
18.
Ruíz-Esquide, Virginia, Pascal Zufferey, Jordi Yagüe, et al.. (2015). OP0032 Relationship Between Clinical Remission and Serum Levels of Tocilizumab in the Treatment of Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 74. 77–77.
19.
Ramírez, Julio, Georgina Salvador, Virginia Ruíz-Esquide, et al.. (2014). Is There Subclinical Synovitis in Patients with Palindromic Rheumatism in the Intercritical Period? A Clinical and Ultrasonographic Study According to Anticitrullinated Protein Antibody Status. The Journal of Rheumatology. 41(8). 1650–1655.
20.
Inciarte-Mundo, J., M.V. Hernández, Virginia Ruíz-Esquide, et al.. (2013). Reducción de dosis de terapias biológicas en enfermedades reumáticas: análisis descriptivo de 153 pacientes en condiciones de práctica clínica. Reumatología Clínica. 10(1). 10–16.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jong-Liang Lan Breakdown of academic impact, for papers by Jean-David Cohen Breakdown of academic impact, for papers by Enrique Raya Breakdown of academic impact, for papers by Sita Bhella Breakdown of academic impact, for papers by Emre Bılgın Breakdown of academic impact, for papers by A Smerdel Breakdown of academic impact, for papers by Shannen Nelson Breakdown of academic impact, for papers by Lieke Tweehuysen Breakdown of academic impact, for papers by Carolina Duarte‐Salazar Breakdown of academic impact, for papers by Maria Domenica Guarino